Vibunazole

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526557

CAS#: 80456-55-9

Description: Vibunazole is an antifungal agent

Chemical Structure

img
Vibunazole
CAS# 80456-55-9
Instruction

Theoretical Analysis

MedKoo Cat#: 526557
Name: Vibunazole
CAS#: 80456-55-9
Chemical Formula: C15H20ClN3O2
Exact Mass: 309.12
Molecular Weight: 309.794
Elemental Analysis: C, 58.16; H, 6.51; Cl, 11.44; N, 13.56; O, 10.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Bay N 7133; BayN 7133; Bay-N 7133; Vibunazole

IUPAC/Chemical Name: 2-((1H-1,2,4-triazol-1-yl)methyl)-1-(4-chlorophenoxy)-3,3-dimethylbutan-2-ol

InChi Key: OCQPZTCGZAFWSG-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H20ClN3O2/c1-14(2,3)15(20,8-19-11-17-10-18-19)9-21-13-6-4-12(16)5-7-13/h4-7,10-11,20H,8-9H2,1-3H3

SMILES Code: OC(COC1=CC=C(Cl)C=C1)(C(C)(C)C)CN2N=CN=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 309.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: van Gulpen C, Kelder O, Mattie H, van der Meer JW, van't Wout J. Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. J Antimicrob Chemother. 1985 Jul;16(1):75-9. PubMed PMID: 4044466.

2: Lefler E, Stevens DA. New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. J Antimicrob Chemother. 1985 Jan;15(1):69-75. PubMed PMID: 3972759.

3: Ritter W, Plempel M. Pharmacokinetics of the oral triazole antimycotic vibunazole in animals. J Antimicrob Chemother. 1984 Sep;14(3):243-52. PubMed PMID: 6490569.

4: Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984 Aug;14(2):105-14. PubMed PMID: 6094418.

5: Ritter W, Holmwood G, Ahr HJ, Detzer K, Kraatz U, Plempel M, Scherling D, Siefert HM. Vibunazole and its enantiomers. Synthesis, antifungal activity, and pharmacokinetics. Ann N Y Acad Sci. 1988;544:74-85. PubMed PMID: 3063187.

6: Schaude M, Meingassner JG. A diffusion chamber technique for testing of antifungal drugs against Sporothrix schenckii in vivo. J Med Vet Mycol. 1986 Aug;24(4):297-304. PubMed PMID: 3018212.

7: Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81-6. PubMed PMID: 2995303.

8: Hiratani T, Yamaguchi H. [Cross-resistance of Candida albicans to several different families of antifungals with ergosterol biosynthesis-inhibiting activity]. Jpn J Antibiot. 1994 Feb;47(2):125-8. Japanese. PubMed PMID: 8151906.

9: Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171-4. PubMed PMID: 3032882.

10: Okeke CN, Gugnani HC. In vitro sensitivity of environmental isolates of pathogenic dematiaceous fungi to azole compounds and a phenylpropyl-morpholine derivative. Mycopathologia. 1987 Sep;99(3):175-81. PubMed PMID: 3657909.

11: Fromtling RA, Abruzzo GK, Bulmer GS. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Mycopathologia. 1986 Apr;94(1):27-30. PubMed PMID: 3014339.

12: Meunier F. Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents. Eur J Clin Microbiol. 1986 Feb;5(1):103-9. PubMed PMID: 3516681.

13: Beggs WH, Hughes CE. Irrelevance of growth phase with respect to the Bay n 7133 and ICI 153,066 susceptibilities of Candida albicans. Diagn Microbiol Infect Dis. 1986 Jan;4(1):83-6. PubMed PMID: 3510807.

14: Hoeprich PD, Merry JM. Activity of BAY n 7133 and BAY 1 9139 in vitro and in experimental murine coccidioidomycosis. Eur J Clin Microbiol. 1985 Aug;4(4):400-3. PubMed PMID: 4043057.

15: Ackerbauer H, Meingassner JG, Mieth H. [Experimental renal infection with Aspergillus fumigatus in mice: a chemotherapeutic model of an organic mycosis]. Mykosen. 1985 May;28(5):244-50. German. PubMed PMID: 2989682.

16: Lefler E, Brummer E, Perlman AM, Stevens DA. Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother. 1985 Mar;27(3):363-6. PubMed PMID: 3994350; PubMed Central PMCID: PMC176278.

17: Lefler E, Brummer E, McEwen JG, Hoyos GL, Restrepo A, Stevens DA. Study of current and new drugs in a murine model of acute paracoccidioidomycosis. Am J Trop Med Hyg. 1985 Jan;34(1):134-40. PubMed PMID: 3970306.

18: Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5-9. PubMed PMID: 6089654; PubMed Central PMCID: PMC179904.

19: Fromtling RA, Yu HP, Shadomy S. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Mycopathologia. 1984 Apr 30;86(1):45-50. PubMed PMID: 6330557.

20: Nusch W, Plempel M. [Microbiological determination of the oral antifungal agent Bay N 7133 and ketoconazole in cervical and vaginal secretion of patients]. Mykosen. 1983 Dec;26(12):600-4. German. PubMed PMID: 6319990.